HealthcareGlobal Alzheimer’s Disease Drug Market by Manufacturers, Countries, Type and Application, Forecast to 2022

  • RnM1150422
  • |
  • 1 April, 2017
  • |
  • Global
  • |
  • 115 pages
  • |
  • GlobalInfoResearch
  • |
  • Healthcare

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

Scope of the Report:
This report focuses on the Alzheimer’s Disease Drug in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck.

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Donepezil
Memantine
Rivastigmine

Market Segment by Applications, can be divided into
Early to Moderate Stages
Moderate to Severe Stages

There are 15 Chapters to deeply display the global Alzheimer’s Disease Drug market.

Chapter 1, to describe Alzheimer’s Disease Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Alzheimer’s Disease Drug, with sales, revenue, and price of Alzheimer’s Disease Drug, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Alzheimer’s Disease Drug, for each region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Alzheimer’s Disease Drug market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022;

Chapter 13, 14 and 15, to describe Alzheimer’s Disease Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

1 Market Overview
1.1 Alzheimer’s Disease Drug Introduction
1.2 Market Analysis by Type
1.2.1 Donepezil
1.2.2 Memantine
1.2.3 Rivastigmine
1.3 Market Analysis by Applications
1.3.1 Early to Moderate Stages
1.3.2 Moderate to Severe Stages
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA Market States and Outlook (2012-2022)
1.4.1.2 Canada Market States and Outlook (2012-2022)
1.4.1.3 Mexico Market States and Outlook (2012-2022)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2012-2022)
1.4.2.2 France Market States and Outlook (2012-2022)
1.4.2.3 UK Market States and Outlook (2012-2022)
1.4.2.4 Russia Market States and Outlook (2012-2022)
1.4.2.5 Italy Market States and Outlook (2012-2022)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2012-2022)
1.4.3.2 Japan Market States and Outlook (2012-2022)
1.4.3.3 Korea Market States and Outlook (2012-2022)
1.4.3.4 India Market States and Outlook (2012-2022)
1.4.3.5 Southeast Asia Market States and Outlook (2012-2022)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2012-2022)
1.4.4.2 Egypt Market States and Outlook (2012-2022)
1.4.4.3 Saudi Arabia Market States and Outlook (2012-2022)
1.4.4.4 South Africa Market States and Outlook (2012-2022)
1.4.4.5 Nigeria Market States and Outlook (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Allergan
2.1.1 Business Overview
2.1.2 Alzheimer’s Disease Drug Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Allergan Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eisai
2.2.1 Business Overview
2.2.2 Alzheimer’s Disease Drug Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Eisai Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Alzheimer’s Disease Drug Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Novartis Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Daiichi Sankyo
2.4.1 Business Overview
2.4.2 Alzheimer’s Disease Drug Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Daiichi Sankyo Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merz Pharma
2.5.1 Business Overview
2.5.2 Alzheimer’s Disease Drug Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Merz Pharma Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Alzheimer’s Disease Drug Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Pfizer Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Alzheimer’s Disease Drug Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Johnson & Johnson Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Lundbeck.
2.8.1 Business Overview
2.8.2 Alzheimer’s Disease Drug Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Lundbeck. Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Alzheimer’s Disease Drug Market Competition, by Manufacturer
3.1 Global Alzheimer’s Disease Drug Sales and Market Share by Manufacturer
3.2 Global Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 Alzheimer’s Disease Drug Manufacturer Market Share
3.3.2 Top 6 Alzheimer’s Disease Drug Manufacturer Market Share
3.4 Market Competition Trend
4 Global Alzheimer’s Disease Drug Market Analysis by Regions
4.1 Global Alzheimer’s Disease Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Alzheimer’s Disease Drug Sales by Regions (2012-2017)
4.1.2 Global Alzheimer’s Disease Drug Revenue by Regions (2012-2017)
4.2 North America Alzheimer’s Disease Drug Sales and Growth (2012-2017)
4.3 Europe Alzheimer’s Disease Drug Sales and Growth (2012-2017)
4.4 Asia-Pacific Alzheimer’s Disease Drug Sales and Growth (2012-2017)
4.5 South America Alzheimer’s Disease Drug Sales and Growth (2012-2017)
4.6 Middle East and Africa Alzheimer’s Disease Drug Sales and Growth (2012-2017)
5 North America Alzheimer’s Disease Drug by Countries
5.1 North America Alzheimer’s Disease Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Alzheimer’s Disease Drug Sales by Countries (2012-2017)
5.1.2 North America Alzheimer’s Disease Drug Revenue by Countries (2012-2017)
5.2 USA Alzheimer’s Disease Drug Sales and Growth (2012-2017)
5.3 Canada Alzheimer’s Disease Drug Sales and Growth (2012-2017)
5.4 Mexico Alzheimer’s Disease Drug Sales and Growth (2012-2017)
6 Europe Alzheimer’s Disease Drug by Countries
6.1 Europe Alzheimer’s Disease Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Alzheimer’s Disease Drug Sales by Countries (2012-2017)
6.1.2 Europe Alzheimer’s Disease Drug Revenue by Countries (2012-2017)
6.2 Germany Alzheimer’s Disease Drug Sales and Growth (2012-2017)
6.3 UK Alzheimer’s Disease Drug Sales and Growth (2012-2017)
6.4 France Alzheimer’s Disease Drug Sales and Growth (2012-2017)
6.5 Russia Alzheimer’s Disease Drug Sales and Growth (2012-2017)
6.6 Italy Alzheimer’s Disease Drug Sales and Growth (2012-2017)
7 Asia-Pacific Alzheimer’s Disease Drug by Countries
7.1 Asia-Pacific Alzheimer’s Disease Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Alzheimer’s Disease Drug Sales by Countries (2012-2017)
7.1.2 Asia-Pacific Alzheimer’s Disease Drug Revenue by Countries (2012-2017)
7.2 China Alzheimer’s Disease Drug Sales and Growth (2012-2017)
7.3 Japan Alzheimer’s Disease Drug Sales and Growth (2012-2017)
7.4 Korea Alzheimer’s Disease Drug Sales and Growth (2012-2017)
7.5 India Alzheimer’s Disease Drug Sales and Growth (2012-2017)
7.6 Southeast Asia Alzheimer’s Disease Drug Sales and Growth (2012-2017)
8 South America Alzheimer’s Disease Drug by Countries
8.1 South America Alzheimer’s Disease Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Alzheimer’s Disease Drug Sales by Countries (2012-2017)
8.1.2 South America Alzheimer’s Disease Drug Revenue by Countries (2012-2017)
8.2 Brazil Alzheimer’s Disease Drug Sales and Growth (2012-2017)
8.3 Argentina Alzheimer’s Disease Drug Sales and Growth (2012-2017)
8.4 Columbia Alzheimer’s Disease Drug Sales and Growth (2012-2017)
9 Middle East and Africa Alzheimer’s Disease Drug by Countries
9.1 Middle East and Africa Alzheimer’s Disease Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Alzheimer’s Disease Drug Sales by Countries (2012-2017)
9.1.2 Middle East and Africa Alzheimer’s Disease Drug Revenue by Countries (2012-2017)
9.2 Saudi Arabia Alzheimer’s Disease Drug Sales and Growth (2012-2017)
9.3 UAE Alzheimer’s Disease Drug Sales and Growth (2012-2017)
9.4 Egypt Alzheimer’s Disease Drug Sales and Growth (2012-2017)
9.5 Nigeria Alzheimer’s Disease Drug Sales and Growth (2012-2017)
9.6 South Africa Alzheimer’s Disease Drug Sales and Growth (2012-2017)
10 Global Alzheimer’s Disease Drug Market Segment by Type
10.1 Global Alzheimer’s Disease Drug Sales, Revenue and Market Share by Type (2012-2017)
10.1.1 Global Alzheimer’s Disease Drug Sales and Market Share by Type (2012-2017)
10.1.2 Global Alzheimer’s Disease Drug Revenue and Market Share by Type (2012-2017)
10.2 Donepezil Sales Growth and Price
10.2.1 Global Donepezil Sales Growth (2012-2017)
10.2.2 Global Donepezil Price (2012-2017)
10.3 Memantine Sales Growth and Price
10.3.1 Global Memantine Sales Growth (2012-2017)
10.3.2 Global Memantine Price (2012-2017)
10.4 Rivastigmine Sales Growth and Price
10.4.1 Global Rivastigmine Sales Growth (2012-2017)
10.4.2 Global Rivastigmine Price (2012-2017)
11 Global Alzheimer’s Disease Drug Market Segment by Application
11.1 Global Alzheimer’s Disease Drug Sales Market Share by Application (2012-2017)
11.2 Early to Moderate Stages Sales Growth (2012-2017)
11.3 Moderate to Severe Stages Sales Growth (2012-2017)
12 Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.1 Global Alzheimer’s Disease Drug Sales, Revenue and Growth Rate (2017-2022)
12.2 Alzheimer’s Disease Drug Market Forecast by Regions (2017-2022)
12.2.1 North America Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.2.2 Europe Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.2.3 Asia-Pacific Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.2.4 South America Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.2.5 Middle East and Africa Alzheimer’s Disease Drug Market Forecast (2017-2022)
12.3 Alzheimer’s Disease Drug Market Forecast by Type (2017-2022)
12.4 Alzheimer’s Disease Drug Market Forecast by Application (2017-2022)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Analyst Introduction
15.3 Data Source

captcha
Please enter code
captcha
Please enter code

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

captcha
Please enter code

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$4,680.00
2,336.82
3,142.62
3,202.30
4,306.54
421,567.20
566,935.20
230,770.63
310,346.71
Add To Cart Credit card Logo

Related Reports


Reason to Buy